Eagle Hopes To Build On Bendamustine Success With Injectable Reformulations

05 Jul 2016

• By Joseph Haas

With concentrated, lower-volume injectables, the specialty firm is finding larger patient bases for the cancer drug bendamustine and the muscle relaxant dantrolene.

Having succeeded with a more rapid infusion formulation of Teva Pharmaceutical Industries Ltd. cancer drug Treanda (bendamustine), specialty firm Eagle Pharmaceuticals Inc. has proof-of-principle for its business model of reformulating injectable products to broaden their reach.

The firm's next step will be to build up its Ryanodex product by adding an indication for exertional heat stroke...